AOD-9604 + Tesamorelin + MOTS-c Blend Peptide

Tesamorelin has been the most extensively studied of the three blend components in controlled clinical trials, providing a robust evidence base for its mechanism-driven effects on visceral adipose tissue (VAT). The landmark trials supporting its mechanism are summarised below.

Phase 3 Trial: Falutz et al. (NEJM 2007)
This multicentre, randomised, double-blind, placebo-controlled trial enrolled 412 HIV-infected adults with excess abdominal fat. Subjects received tesamorelin 2 mg subcutaneously daily or placebo for 26 weeks.

• Visceral adipose tissue decreased by 15.2% in the tesamorelin group versus a 5.0% increase in placebo (p<0.001)
• IGF-1 levels rose by a mean of 106 µg/L in treated subjects, confirming GH-axis activation
• Trunk fat decreased by 1.0 kg versus no change in placebo
• Subcutaneous adipose tissue was not significantly affected — supporting the visceral-selective profile
• Fasting glucose and HbA1c were unchanged at 26 weeks

Extension Trial: Falutz et al. (JCEM 2010)
A 52-week extension of the pivotal trial assessed sustained VAT reduction. Subjects continuing tesamorelin maintained an 18% reduction in VAT from baseline, while those switched to placebo showed regression toward baseline within 26 weeks, demonstrating that the effect requires continued GHRH-receptor activation rather than producing a durable structural change.

AOD-9604 Preclinical Lipolysis Data
Heffernan et al. (Endocrinology, 2001) demonstrated that AOD-9604 administered to obese (ob/ob) mice produced reductions in body fat comparable to full-length hGH but without the hyperglycaemic side effects. Using β3-AR knockout mice, the authors confirmed that the lipolytic effect was substantially attenuated in the absence of β3-AR, providing receptor-level mechanistic confirmation.

MOTS-c Metabolic Model Data
Lee et al. (Cell Metabolism, 2015) reported that exogenous MOTS-c administration (0.5 mg/kg/day IP) to high-fat-diet mice for 7 weeks reduced weight gain by approximately 40% versus controls and normalised glucose tolerance. Skeletal muscle showed activation of AMPK and downstream metabolic gene expression. These data established MOTS-c as a functional mitokine relevant to metabolic dysregulation models.

Combined-Use Research Context
No peer-reviewed clinical trial has directly evaluated the AOD-9604 + Tesamorelin + MOTS-c combination. Research interest in the blend derives from the orthogonal nature of the three mechanisms, allowing investigators to design preclinical protocols that probe whether peripheral lipolytic stimulation (AOD-9604), central GH-axis activation (Tesamorelin), and mitochondrial AMPK signalling (MOTS-c) produce additive effects on adipose mass, energy expenditure, and metabolic markers in animal models. Such studies remain investigational and are intended strictly for laboratory research use.

AOD-9604 is a synthetic peptide fragment corresponding to the C-terminus (amino acids 177–191) of human growth hormone, originally developed by Metabolic Pharmaceuticals as an investigational anti-obesity agent. The lipolytic domain of hGH was identified in foundational work by Ng and Bornstein, who demonstrated that the carboxyl-terminal region of growth hormone retained fat-mobilising activity independent of the somatogenic and diabetogenic effects of the parent hormone.^[1]

Preclinical Lipolysis Data:

• In ob/ob obese mouse models, repeated administration of AOD-9604 was associated with significant reductions in body weight gain and adipose tissue mass compared to vehicle controls.
• Studies in isolated rodent adipocytes demonstrated a dose-dependent increase in lipolytic activity, measured by glycerol release into the culture medium.
• In vitro work indicated AOD-9604 stimulated β3-adrenergic receptor expression and upregulated hormone-sensitive lipase activity, contributing to enhanced triglyceride hydrolysis.
• Unlike full-length growth hormone, AOD-9604 did not produce hyperglycemia or insulin resistance in preclinical models, a feature attributed to the absence of the somatogenic domain.^[2]

Clinical Investigation Summary:

In a 12-week randomised, placebo-controlled Phase 2b clinical trial conducted in obese subjects (BMI ≥30 kg/m²), AOD-9604 administered at doses of 1 mg daily was investigated for weight reduction endpoints. While the compound demonstrated an excellent safety profile and was well tolerated, the magnitude of weight loss in human subjects was modest compared to preclinical predictions, and clinical development for obesity was ultimately discontinued. Notably, AOD-9604 did not affect IGF-1 levels, glucose tolerance, or insulin sensitivity — distinguishing it from full-length GH analogues such as tesamorelin's downstream effects.

Relevance to the Blend:

Within the AOD-9604 + Tesamorelin + MOTS-c research blend, AOD-9604 contributes a GH-fragment-mediated lipolytic signal that operates downstream of (and complementary to) tesamorelin's GHRH-driven endogenous GH release. This layered approach allows researchers to model whether peripheral lipolytic stimulation (AOD-9604) plus central GH-axis activation (tesamorelin) plus mitochondrial substrate-switching (MOTS-c) produce additive or synergistic effects on adipose tissue metabolism in vitro and in animal models. The blend is particularly suited for studies examining adipocyte differentiation, lipid droplet dynamics, and the crosstalk between GH-axis signalling and mitochondrial energy homeostasis.

Research Note: AOD-9604 is not approved for human therapeutic use in any jurisdiction. It is supplied strictly for in vitro and preclinical research applications.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the small mitochondrial ribosomal RNA gene. It was first characterised by Lee and colleagues at the University of Southern California in 2015, who demonstrated that MOTS-c regulates insulin sensitivity and metabolic homeostasis through AMPK-dependent mechanisms.^[1]

Landmark Discovery Study (Lee et al., 2015):

• MOTS-c was identified as an endogenously encoded peptide that translocates to the nucleus in response to metabolic stress, where it regulates adaptive nuclear gene expression.
• In high-fat-diet-fed mice, daily intraperitoneal MOTS-c administration prevented diet-induced obesity and reversed age-dependent insulin resistance.
• Treated animals showed improved glucose tolerance, reduced fat mass, and enhanced metabolic flexibility, measured via indirect calorimetry.
• The peptide was shown to activate AMP-activated protein kinase (AMPK), the master cellular energy sensor, leading to enhanced glucose uptake and fatty acid oxidation in skeletal muscle.

Folate-Methionine-AICAR Axis:

Mechanistically, MOTS-c interferes with the folate cycle, leading to accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an endogenous AMPK activator. This creates a metabolic state functionally analogous to caloric restriction or exercise — promoting fatty acid oxidation, mitochondrial biogenesis, and improved insulin sensitivity without requiring reduced food intake.

Exercise-Mimetic Properties:

Subsequent research by Reynolds et al. (2021) demonstrated that MOTS-c functions as an exercise-induced mitochondrial-derived peptide. Circulating MOTS-c levels rose acutely in human subjects after a single bout of aerobic exercise, and skeletal muscle expression of MOTS-c increased after exercise training.^[2] In aged mice, MOTS-c treatment improved physical performance metrics including running endurance, grip strength, and gait, suggesting application in studies of sarcopenia and age-related metabolic decline.

Relevance to the Blend:

Within the AOD-9604 + Tesamorelin + MOTS-c research blend, MOTS-c provides a mitochondrial-level metabolic signal distinct from the GH-axis pathways activated by tesamorelin and AOD-9604. By engaging AMPK and promoting substrate oxidation, MOTS-c complements the lipolytic and GH-releasing arms of the blend, allowing researchers to study how convergent mitochondrial, pituitary, and adipocyte signalling integrate to regulate whole-organism energy balance in preclinical models. This makes the blend a useful tool for investigating the intersection of growth hormone axis biology and mitochondrial-derived peptide signalling.